CIMAvax-EGF is a new lung cancer treatment that “harnesses the body’s immune system to fight lung cancer.” They began testing the drug in 2017; another trial is testing the drug for the prevention of lung cancer in patients who are at high risk.
CIMAvax-EGF blocks a certain protein (epidermal growth factor (EGF)) that cancer cells need to grow. The drug works by starving the cancer cells by preventing EGF from attaching to the cell. If the cancer cell cannot multiply, it dies.
They have treated more than 5,000 lung cancer patients so far with this unique immunotherapy. Several international studies have indicated prolonged tumor stabilization and improved overall survival and quality of life for patients receiving CIMAvax. CIMAvax is an approved treatment for lung cancer in Argentina, Bosnia and Herzegovina, Colombia, Cuba, Kazakhstan, Paraguay, and Peru.
Groundbreaking drugs like CIMAvax, give hope to those with mesothelioma. Could a mesothelioma vaccine be next?
If you have been diagnosed with mesothelioma, contact one of our attorneys today. You may be entitled to compensation.